The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody.
By D. Benson, C. Bakan, A. Mishra, C. Hofmeister, Y. Efebera, B. Becknell, R. Baiocchi, Jianying Zhang, Jianhua Yu, Megan K. Smith and 7 more. Blood, 2010
789 citations recorded by the source corpus.
Subfields: Immunology, Oncology
View Paper: https://www.semanticscholar.org/paper/41aea3b5733cbc677a3cb92a11caaee896c21379
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
- D. Pardoll
- Timothy A. Chan
- S. Topalian
- Charles G. Drake
- J. Wolchok
- Lieping Chen
- Antoni Ribas
- Jacques Banchereau
In Oncology
- D. Pardoll
- Timothy A. Chan
- S. Topalian
- Charles G. Drake
- J. Wolchok
- Antoni Ribas
- Lieping Chen
- M. Smyth
Citations in the corpus
- PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. (2013, background): “This antibody has already been validated in ex vivo functional assays in humans (24).”
- Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors (2011, background): “(45) showed that upregulated expression of the program death receptor-1 on NK cells of MM patients”
- Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity (2012, positive): “demonstrated its capacity to activate human NK cells against multiple myeloma, suggesting engagement of the innate immune system [42].”
- The head and neck cancer immune landscape and its immunotherapeutic implications. (2016, background): “Recent evidence has shown that the PD-1 receptor (commonly found on T cells) can also be found on activated NK cells (72, 73).”